Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
Firas Hamdan(University of Helsinki), Vincenzo Cerullo(University of Helsinki)
Cited by 53
Related Papers
CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging
|Gene Therapy|2013|42
Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses
|OncoImmunology|2024|11
Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy
|Molecular Therapy Oncology|2024|6